Partial response of a rare malignant metastatic diffuse tenosynovial giant cell tumor with benign histologic features, treated with SCH 717-454, an insulin growth factor receptor inhibitor, in combination with everolimus, an MTOR inhibitor

Targeted Oncology

Volumn 9, Issue 1, 2014, Pages 73-79

  Sikaria, Swati ^a   Heim Hall, Josefine ^b   Diaz, Elizabeth H ^b   Williams, Ronald ^b   Sankhala, Kamelesh ^b   Laabs, Brenda ^b   Mita, Monica ^a,b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

IGFR inhibitor; mTOR inhibitor; Tenosynovial giant cell tumor

Indexed keywords

EVEROLIMUS; HEMOGLOBIN; IMATINIB; ROBATUMUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; MTOR PROTEIN, HUMAN; RAPAMYCIN; SOMATOMEDIN RECEPTOR; TARGET OF RAPAMYCIN KINASE;

ADULT; ANEMIA; ARM AMPUTATION; ARM PAIN; ARM SWELLING; ARTERY OCCLUSION; ARTICLE; AXILLARY ARTERY; AXILLARY LYMPH NODE; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RECURRENCE; CASE REPORT; CELLULITIS; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL OBSTRUCTION; GIANT CELL TUMOR; HERBAL MEDICINE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERLIPIDEMIA; LUNG METASTASIS; LYMPH NODE BIOPSY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SUBCLAVIAN ARTERY; TENOSYNOVIAL GIANT CELL TUMOR; THROMBOCYTOSIS; TREATMENT OUTCOME; TUMOR BIOPSY; TUMOR LOCALIZATION; TUMOR VOLUME; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; GIANT CELL TUMORS; IMMUNOLOGY; JOINT CAPSULE; METASTASIS; MIDDLE AGED; PATHOLOGY; SHOULDER; SOFT TISSUE NEOPLASMS; TENDON;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; GIANT CELL TUMORS; HUMANS; JOINT CAPSULE; MALE; MIDDLE AGED; NEOPLASM METASTASIS; RECEPTORS, SOMATOMEDIN; SHOULDER JOINT; SIROLIMUS; SOFT TISSUE NEOPLASMS; TENDONS; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME;

EID: 84899532050     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-013-0267-8     Document Type: Article

References (22)

1. Li CF, Wang J, Huang W, Hou C, Chou S, Eng JH, Lin C, Yu S, Huang H (2008) Malignant diffuse-type tenosynovial giant cell tumors: a series of 7 cases comparing with 24 benign lesions with review of the literature. Am J Surg Pathol 32:587-599 (Pubitemid 351458301)
2. Cassier JA, Blay JY et al (2012) Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis. Cancer 118(6):1649-1655
3. Somerhausen N, Fletcher C (2000) Diffuse-type giant cell tumor clinicopathologic and immunohistochemical analysis of 50 cases with extraarticular disease. Am J Surg Path 24(4):479-492 (Pubitemid 30180741)
4. Ravi V, Wang W, Lewis VO (2011) Treatment of tenosynovial giant cell tumor and pigmented villondular synovitis. Curr Opin Oncol 23:361-366
5. Chin KR, Barr SJ, Winalski C et al (2002) Treatment of advanced primary and recurrent diffuse pigmented villonodular synovitis of the knee. J Bone Joint Surg Am 84-A:2192-2202 (Pubitemid 35417699)
6. Cheng H, Clarkson PW, Gao D, Pacheco M, Wang Y, Nielson TO (2010) Therapeutic antibodies targeting CSF1 impede macrophage recruitment in a xenograft model of tenosynovial giant cell tumor. Sarcoma. doi:10.1155/2010/ 174528
7. Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE (2000) The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 21(3):215-244 (Pubitemid 32275588)
8. Giustina A, Mazziotti G, Canalis E (2006) Growth hormone, insulin-like growth factors, and the skeleton. Endocr Rev 29(5):535-559
9. Myers MG Jr, Sun XJ, Cheatham B, Jachna BR, Glasheem EM, Backer JM, White MF (1993) IRS-1 is a common element in insulin and insulin-like growth factor-1 signaling to the phosphatidylinositol 3′-kinase. Endocrinology 132:1421-1430 (Pubitemid 23110508)
10. Raile K, Höflich A, Kessler U et al (1994) Human osteosarcoma (U-2 OS) cells express both insulin-like growth factor-I (IGF-I) receptors and insulin-like growth factor-II/mannose-6-phosphate (IGF-II/M6P) receptors and synthesize IGF-II: autocrine growth stimulation by IGF-II via the IGF-I receptor. J Cell Physiol 159(3):531-541
11. Burrow S, Andrulis IL, Pollak M, Bell RS (1998) Expression of insulin-like growth factor receptor, IGF-1, and IGF-2 in primary and metastatic osteosarcoma. J Surg Onc 69:21-27 (Pubitemid 28452269)
12. Steigen SE, Schaeffer DF, West RB, Nielsen TO (2009) Expression of insulin-like growth factor 2 in mesenchymal neoplasms. Modern Path 22:914-921
13. Pollack MN, Polychronakos C, Richard M (1990) Insulin-like growth factor-I: a potent mitogen for human osteogenic sarcoma. J Natl Cancer Inst 82:301-305 (Pubitemid 20097703)
14. Wang Y, Lipari P, Wang X et al (2010) A fully human insulin-like growth factor-I receptor antibody SCH 717454 (Robatumumab) has antitumor activity as a single agent and in combination with cytotoxics in pediatric tumor xenografts. Mol Cancer Ther 9:410
15. Tolcher AW, Sarantopoulos J, Patnaik A et al (2009) Phase I, pharmacokinetic and pharmacodynamic study of AMG 479, a fully human monoclo nal antibody to insulin-like growth factor receptor 1. J Clin Oncol 27(34):5800-5807
16. Olmos D, Postel-Vinay S, Molife LR et al (2010) Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase I expansion cohort study. Lancet Oncol 11(2):129-135
17. Papp AS, Patel S, Crowley J et al (2010) Activity of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF1R), in patients (pts) with recurrent or refractory Ewing's sarcoma family of tumors (ESFT): results of a phase II SARC study. J Clin Oncol 28:15s
18. Mita MM, Tolcher AW (2007) The role of mTOR inhibitors for treatment of sarcomas. Curr Onc Rep 9:316-322 (Pubitemid 47045166)
19. Dumez H (2008) A phase I-II study of everoilmus (RAD001) in combination with imatinib in patients with imatinib resistant gastrointestinal stromal tumors (GIST). J Clin Oncol 21(10):1990-1998
20. Chawla SP, Blay J, Ray-Coquard IL, Cesne AL, Staddon AP, et al. (2011) Results of the phase III, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus (R) as maintenance therapy in advanced sarcoma patients (pts) following clinical benefit from prior standard cytotoxic chemotherapy (CT). J Clin Oncol 29 (suppl; abstr 10005)
21. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D et al (2006) mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66:1500-1508 (Pubitemid 43259931)
22. Quek R,Wang Q, Morgan JA et al (2011) Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors. Clin Cancer Res 17:871-879